Subcutaneous Aspart Insulin to Treat Diabetic Ketoacidosis (DKA) and Beta-Hydroxybutyrate Testing in DKA

N/ACompletedNCT00920725

Rush University Medical Center50 enrolled

Overview

The purpose of this study is to determine whether insulin administered by a subcutaneous injection is effective in the treatment of a diabetic crisis and to determine if beta-hydroxybutyrate is useful to monitor during treatment of a diabetic crisis.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Diabetic Ketoacidosis

Interventions

Insulin (Aspart Insulin [Novolog], Regular Insulin)DRUG

Aspart Insulin 0.2units/sq q 2 hours Regular Insulin 0.1units/kg/hr intravenous Aspart Insulin 0.1 units/kg/hr intravenous

Eligibility

Sex: ALLMin age: 18 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: age 18 or older * venous pH \< 7.3 or arterial \< 7.35 * at least 2 of the following 3: 1. serum HCO3 \< 18/anion gap \> 16 2. serum glucose \> 300 mg/dl 3. serum acetone positive Exclusion Criteria: * pregnant * less than age 18

Locations (1)

Rush University Medical Center

Chicago, Illinois, United States

Outcomes

Primary Outcomes

Hours to resolution of ketoacidosis as defined as beta-hydroxybutyrate <0.6

Time frame: q 2 hours

Hours to achieve blood glucose less than 200mg/dl

Time frame: q 1 hour

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.